ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET
Company Participants
Alex Straus – Investor Relations
Richard Lowenthal – Co-Founder, President and CEO
Eric Karas – Chief Commercial Office
Kathleen Scott – CFO
Justin Chakma – Chief Business Officer
Conference Call Participants
Josh Schimmer – Cantor Fitzgerald
Ryan Deschner – Raymond James
Roanna Ruiz – Leerink Partners
Lachlan Hanbury-Brown – William Blair
Operator
Good day, and welcome to the ARS Pharmaceuticals Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Instructions will be given at that time. As a reminder, this call may be recorded.
I would now like to turn the call over to Alex Straus of Investor Relations. Please go ahead.
Alex Straus
Good morning and thank you for joining. With me on the call today are Richard Lowenthal, Co-Founder, President and CEO of ARS; Eric Karas, our Chief Commercial Office; Kathy Scott, our CFO; and Justin Chakma, our Chief Business Officer.
Earlier today, we issued a press release detailing our third quarter 2024 results and recent business highlights, which can be found on our website at ars-pharma.com. For today’s call, Rich will provide an overview of our recent corporate developments, Eric will provide an update on our neffy commercialization efforts, Kathy will provide a brief overview of our financial results, and the full team will join us for Q&A.
During today’s call, we’ll be making forward-looking statements based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please see the risk factors in our SEC filings for additional details.
Now, let me turn the call over to Rich.
Richard Lowenthal
Thank you, Alex, and
Read the full article here